Lotus Apothecary

Project Alleviate

 

 
 
Company Info Products & Services Business Development Knowledge & News Testimonials


Viral Vector Vaccines

This business field is another possibility to be handled by Lotus Apothecary Project Alleviate property. Actually, this area is being intensively researched and studied worldwide by a number of well-known scientific groups and institutions. Lotus Apothecary Project Alleviate has established close contacts to the medical-virological, scientific group of Prof. Dr. Voflcer Erfle, director of the clinic center of Rechts der Isar, Technical University of Munich. A concept of cooperation is under discussion.

Lotus Apothecary Project Alleviate's part should be to transmit scientifically invented vaccines from laboratory scale to sterile GMP processes to test the vaccine candidates in first clinical trials. Only very small quantities arc required for the manufacturing of those first GMP complying vaccine test materials. As already mentioned above, there arc gaps of suitable capacities in Germany up to now. Lotus Apothecary Project Alleviate's actual sod extendable concept offers an advantageous and commercially attractive solution to all parties involved.
The current class of vaccines under consideration is mainly based on the vector MVA which is a world-wide used attenuated pox virus strain, and recombinant prepared proteins. Further product lines show good perspectives in the scientific area.
The main use for these products is intended to be the treatment of HIV and hepatitis C.


 

For Cancer Patients

Learn about our new Immune Modulators

Learn about Pleo-morphism

 

 


 
 

Lotus Apothecary Project Alleviate; Head office (NV), Administration office (NV)